Oncopharmpod
Olaratumab, Goodbye?
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:18:06
- Mas informaciones
Informações:
Sinopsis
Olaratumab received accelerated approval in 2016 under the condition a phase III study would confirm its benefit. It didn't. We explore some possible explanations why a seemingly promising drug for a tough disease hasn't panned out...
